The HSP90AB1 Knockout HEK293T Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population designed to disrupt the HSP90AB1 gene in the HEK293T host background, generating a heterogeneous loss-of-function model for studying HSP90??-dependent biology. This format avoids clonal artefacts and allows investigation of the collective impact of gene disruption on proteostasis, signal transduction, and cellular physiology.
HEK293T is a human embryonic kidney epithelial cell line transformed with adenovirus 5 DNA and constitutively expressing SV40 large T antigen. These features confer high transfectability, robust episomal amplification of plasmids, and exceptional productivity for recombinant protein expression and lentiviral packaging, establishing HEK293T as a gold-standard host for mechanistic cell biology, drug screening, and viral production applications.
HSP90AB1 encodes HSP90??, the constitutively active isoform of the HSP90 molecular chaperone. It operates through an ATP-dependent cycle, engaging co-chaperones such as CDC37, HOP (STIP1), AHA1, p23 (PTGES3), and immunophilins FKBP5/FKBP4 to fold and stabilize numerous client proteins, including the kinases AKT, RAF, and CDK4, steroid hormone receptors (androgen and estrogen receptors), and transcription factors p53 and NF-??B. Chaperone function is induced by heat shock and oxidative stress via HSF1 and further tuned by Akt-mediated phosphorylation and SIRT1 deacetylation. By ensuring proper client maturation, HSP90?? sustains PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, JAK/STAT, NF-??B, and steroid receptor signaling; its disruption triggers client misfolding and proteasomal degradation.
In HEK293T cells, knockout of HSP90AB1 enables dissection of immediate HSP90??-requiring signaling events in a widely tractable host. The polyclonal population mitigates selection-related biases while providing a clear window into the destabilization of client kinases such as AKT and RAF, leading to attenuated downstream effector phosphorylation, altered cell cycle progression, and enhanced sensitivity to apoptotic cues. This model is therefore suited for interrogating endogenous HSP90??-client dynamics and for evaluating the cellular consequences of chaperone inhibition.
Key applications include western blotting and RT-qPCR to confirm knockout and client depletion, co-immunoprecipitation to profile residual chaperone complexes, and phospho-flow cytometry to quantify signaling perturbations (e.g., phospho-AKT, phospho-ERK). Apoptosis and cell cycle assays complement dose-response studies with HSP90 inhibitors (geldanamycin, 17-AAG) to assess target engagement and isoform selectivity. Additional uses encompass immunofluorescence to track client localization, HSF1 reporter assays, and functional rescue experiments. For further technical details or to request a quotation, contact Ascent Research.
